Engineered CHMO Biocatalysts for High-Purity Armodafinil Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemical processes for preparing armodafinil suffer from poor enantioselectivity and yield, making them inefficient for large-scale production with high substrate loadings.
Innovation Solution
Development of non-naturally occurring polypeptides with cyclohexanone monooxygenase (CHMO) activity, which can efficiently convert amide or acid substrates to armodafinil with high enantiomeric excess and increased activity, even at high substrate concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical processes (Kagan Sharpless-type oxidation or classic resolution) are used to prepare armodafinil, then the synthesis can be performed with existing methodologies, but the enantioselectivity and yield are poor
Solution Approach 1:
The patent applies parameter changes by modifying the enzyme's amino acid sequence through site-directed mutagenesis. Specific residues (e.g., Phe277→Ile, Arg278→Gly, Met280→Thr, Phe281→Ile, Lys326→Arg, Phe432→Ser, Thr433→Gly, Leu435→Ala, Trp490→Leu) are changed to optimize the enzyme's substrate binding and catalytic properties, thereby improving both enantioselectivity and yield of armodafinil production
Solution Approach 2:
The patent uses an engineered cyclohexanone monooxygenase (CHMO) enzyme as an intermediary biocatalyst to mediate the oxidation of 2-(benzhydrylsulfinyl)acetamide to armodafinil. This biocatalytic intermediary provides high enantioselectivity and yield, overcoming the limitations of direct chemical oxidation methods
2Productivity
If natural CHMO enzymes are used for biocatalytic conversion, then the process can be performed with natural enzymes, but the activity is insufficient even at high substrate loadings
Solution Approach 1:
The patent dramatically increases enzyme activity through multiple amino acid substitutions in the CHMO protein sequence. The engineered enzyme exhibits up to 60-fold higher specific activity compared to the wild-type enzyme, enabling efficient conversion at high substrate loadings (≥10 g/L) that were previously ineffective with natural enzymes
3Manufacturing precision
If wild-type CHMO is used for sulfoxidation, then the enzyme can catalyze the reaction, but the enantiomeric excess is insufficient (S:R ratio of 86:13)
Solution Approach 1:
The patent achieves high enantiomeric excess (≥90% ee) by changing multiple amino acid residues in the CHMO enzyme, particularly in the substrate binding pocket. These changes (e.g., Phe277→Ile, Arg278→Gly, Met280→Thr) create a more restrictive chiral environment that strongly favors formation of the (R)-enantiomer, reversing and enhancing the wild-type's preference for the (S)-enantiomer
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered CHMO polypeptides achieve high enantiomeric excess (at least 90%) and increased activity (up to 60-fold) in converting substrates to armodafinil, overcoming the limitations of natural enzymes and enabling efficient large-scale production.
Implementation Method 1
Development of non-naturally occurring polypeptides with cyclohexanone monooxygenase (CHMO) activity, which can efficiently convert amide or acid substrates to armodafinil
Implementation Method 2
The CHMO biocatalytic reaction uses O2 and a co-factor NAPDH to generate the caprolactone, oxidized cofactor NADP+, and H2O
Data Source
AI summary
The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.